Narin Apisarnthanarax is a Dermatology physician. OpenAlex indexes 23 publications with 1,021 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13938 Highway 3 Unit 100
Webster, TX 775981622
Telephone
281-332-9681Provider last certified this registry record 24 Aug 2022.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- REVANCE THERAPEUTICS, INC.Program year20259 payments
- UCB, Inc.Program year20255 payments
- Novartis Pharmaceuticals CorporationProgram year202524 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
26.3%Corticosteroid20.6%Triamcinolone Acetonide62%Triamcinolone acetonide27%Halobetasol Propionate10%Part D + Part B≥109 patientsInterleukin-4 Receptor alpha Antagonist2.7%Dupixent Pen100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
25.4%Azole Antifungal11.5%Ketoconazole100%Part D≥68 patientsTetracycline-class Drug11.3%Doxycycline Hyclate72%Doxycycline Monohydrate28%Part D≥50 patients+ 2 more classes in this area
Sensory organs
19.6%Corticosteroid19.6%Hydrocortisone66%Betamethasone Dipropionate20%Clobetasol Propionate13%Part D≥100 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Usefulness of flow cytometry in the diagnosis of mycosis fungoides
Journal of the American Academy of Dermatology
2007 - Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell Lymphoma
Clinical Lymphoma & Myeloma
2006 - CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma
Journal of Investigative Dermatology
2006 - Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study
Journal of the American Academy of Dermatology
2004
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”